Multi-Maintenance Olaparib Therapy for Relapsed Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial
Clin. Cancer Res 2023 Feb 17;[EPub Ahead of Print], RD Morgan, AR Clamp, DJ White, M Price, GJ Burghel, WDJ Ryder, RD Mahmood, AD Murphy, J Hasan, CL Mitchell, Z Salih, C Wheeler, E Buckley, J Truelove, G King, Y Ainaoui, SS Bhaskar, J Shaw, DGR Evans, B Kilerci, SP Pearce, G Brady, C Dive, JPB O'Connor, AJ Wallace, DG Rothwell, RJ Edmondson, GC JaysonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.